2020
DOI: 10.1080/09537104.2020.1822521
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of immune thrombocytopenia (ITP) secondary to malignancy: a systematic review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 36 publications
0
4
1
Order By: Relevance
“…Pathophysiology of secondary ITP with malignant disorders could be different from that of primary ITP. Previous report demonstrated worse response to corticosteroid in secondary ITP patients with malignancy [28]. Although we have no definitive conclusion, different pathophysiology of secondary ITP with malignant tumour may affect platelet counts within a week.…”
Section: Discussioncontrasting
confidence: 63%
“…Pathophysiology of secondary ITP with malignant disorders could be different from that of primary ITP. Previous report demonstrated worse response to corticosteroid in secondary ITP patients with malignancy [28]. Although we have no definitive conclusion, different pathophysiology of secondary ITP with malignant tumour may affect platelet counts within a week.…”
Section: Discussioncontrasting
confidence: 63%
“…In practice, such a definition could also signal the need for additional investigations, including a first or repeat bone marrow examination, 7 review of the blood film, 12 genetic tests for hereditary thrombocytopenia syndromes 11 or other tests to rule out non‐immune causes of the thrombocytopenia. Poor response to typical ITP treatments may also indicate certain causes of secondary ITP that are often difficult to treat, including ITP in the setting of common variable immune deficiency, autoimmune diseases such as systemic lupus erythematosus, cytomegalovirus infection and lymphoproliferative malignancies 11,19 . A universal definition of refractory ITP would also provide a framework for basic mechanistic studies 11 to explore concepts such as epitope spreading, drug resistance, 20 expansion of abnormal immune cells 21,22 and loss of anti‐platelet antibodies 23 .…”
Section: Definitions Of Refractory Itpmentioning
confidence: 99%
“…Poor response to typical ITP treatments may also indicate certain causes of secondary ITP that are often difficult to treat, including ITP in the setting of common variable immune deficiency, autoimmune diseases such as systemic lupus erythematosus, cytomegalovirus infection and lymphoproliferative malignancies. 11,19 A universal definition of refractory ITP would also provide a framework for basic mechanistic studies 11 to explore concepts such as epitope spreading, drug resistance, 20 expansion of abnormal immune cells 21,22 and loss of anti-platelet antibodies. 23 These mechanisms could explain a change in treatment responsiveness over time.…”
Section: On the Need For A New Definitionmentioning
confidence: 99%
“…Patients who develop thrombocytopenia (as defined by a platelet count < 100,000 platelets per microliter) with no clear underlying cause are usually diagnosed with (isolated) primary ITP [ 2 ], whereas secondary ITP is defined as an ITP induced by other disorders or treatments [ 2 , 3 ]. These may include autoimmune disorders [ 1 , 2 ], solid tumors and lymphoproliferative diseases [ 4 , 5 ] as well as infectious agents [ 6 ], transfusions and drugs (such as interferon) [ 2 , 7 ]. ITP has also been described in children following vaccinations [ 8 ], although this is exceedingly rare [ 2 ].…”
Section: Introductionmentioning
confidence: 99%